Gilead Sciences | GILD - Operating Profit



Gilead Sciences reported $2.7B in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
AbbVie USD 5.72B 1.98B Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
ALKERMES USD 92.98M 79.19M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Bristol-Myers Squibb USD 3.77B 366M Jun/2025
Eli Lilly USD 7.02B 1.61B Jun/2025
Gilead Sciences USD 2.7B 467M Jun/2025
GlaxoSmithKline GBP 2.02B 193M Jun/2025
Glaxosmithkline GBP 2.44B 1.74B Jun/2025
Incyte USD 310.82M 105.66M Jun/2025
J&J USD 6.94B 6.69B Jun/2025
Merck USD 6.36B 494M Jun/2025
Moderna USD -907000000 143M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Novartis USD 4.86B 201M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Regeneron Pharmaceuticals USD 1.08B 487.8M Jun/2025
Sanofi EUR 1.71B 573M Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
United Therapeutics USD 276.9M 105.9M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025